RCC is the most common form of kidney cancer, which is among the 10 most frequently diagnosed cancers in the U.S. annually.
The approval is based on results from CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of Cabometyx and Opdivo compared with sunitinib in previously untreated advanced or metastatic RCC. These results were presented during the European Society of Medical Oncology Virtual Congress 2020 in September.
The FDA reviewed the application for Cabometyx and Opdivo under the Real-Time Oncology Review pilot program and Fast Track designation.
The RTOR pilot program, which allows an applicant to pre-submit components of the application to allow the FDA to review clinical trial data before the complete filing is submitted, aims to explore a more efficient review process to ensure safe and effective treatments are available to patients sooner.
In CheckMate -9ER, the combination regimen significantly improved overall survival compared with sunitinib (HR= 0.60, 98.89% CI 0.40-0.89; p=0.001).
Median OS has not yet been reached in either treatment arm. Median progression-free survival was doubled at 16.6 months for Cabometyx in combination with Opdivo compared with 8.3 months for sunitinib (HR 0.51, 95% CI 0.41-0.64; p
Sanofi receives US fast track designation for gene therapy targeting geographic atrophy
Currax expands access to Contrave obesity treatment
Varian launches IntelliBlate in Europe, expanding image-guided microwave ablation for cancer care
Biophytis partners with Lynx Analytics to advance AI-driven drug discovery for sarcopenia
Niagen Bioscience introduces Tru Niagen and Niagen IV at Equinox Hotel New York
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
GSK announces submission of RSV vaccine Arexvy for FDA review
Imugene announces Azer-cel Phase 1b clinical trial data
FDA approves Merck Animal Health's once-yearly flea and tick treatment for dogs